Manejo actual del paciente con CPNM con reordenamiento ALK/ROS1

Shaw, et al. WCLC 2015; Ou, et al. ASCO 2015;

Alectinib

(n=70)

Chemotherapy

(n=34)

All Grade Adverse Events (AEs)

54 (77.1%)

Serious AEs

13 (18.6%)

5 (14.7%)

Grade 3-5 AEs

19 (27.1%)

14 (41.2%)

Fatal AEs

0 (0%)

1 (2.9%)

AEs leading to treatment discontinuation

4 (5.7%)

3 (8.8%)

AEs leading to dose reduction

3 (4.3%)

4 (11.8%)

AEs leading to dose interruption

13 (18.6%)

3 (8.8%)

ALUR: phase III trial of alectinib versus

chemotherapy in previously treated ALK+ NSCLC